Assessment of the changes in 9L and C6 glioma pO2 by EPR oximetry as a prognostic indicator of differential response to radiotherapy.
Assessment of the changes in 9L and C6 glioma pO2 by EPR oximetry as a prognostic indicator of differential response to radiotherapy.
复制标题
DOI：
10.1667/rr2811.1
复制
发表时间：
2013-03
影响因子：
3.4
通讯作者：
Khan N
中科院分区：
文献类型：
--
作者：
Hou H;Mupparaju SP;Lariviere JP;Hodge S;Gui J;Swartz HM;Khan N
肿瘤缺氧影响放疗效果。由于实体瘤中缺氧的程度在放疗过程中会发生变化，因此可以提供肿瘤pO 2重复评估的方法（如EPR血氧测定法）可以通过在肿瘤氧合时安排辐照来增强放疗的疗效。肿瘤pO 2的重复测量也可以识别应答者，从而有助于为无应答肿瘤设计更好的治疗计划。我们已经调查了时间的变化，异位9 L和C6胶质瘤pO 2照射单次辐射剂量小于10戈伊的EPR血氧饱和度。9 L和C6肿瘤缺氧，pO 2约为5-9 mmHg。4.8-9.3戈伊照射后，C6肿瘤的pO 2明显升高。然而，未观察到9 L肿瘤pO 2的变化。与低氧和2戈伊× 5治疗组相比，用第二剂量4.8戈伊照射充氧C6肿瘤导致生长显著延迟。与无应答者相比，pO 2从4.8戈伊照射基线增加大于50%的C6肿瘤（应答者）具有显著的肿瘤生长延迟。这些结果表明异位9 L和C6肿瘤对放射治疗的反应不同。我们建议在放射治疗期间重复测量肿瘤中的氧水平可以用于识别应答者并设计肿瘤氧引导治疗计划以改善结果。
Tumor hypoxia impedes the outcome of radiotherapy. As the extent of hypoxia in solid tumors varies during the course of radiotherapy, methods that can provide repeated assessment of tumor pO2 such as EPR oximetry may enhance the efficacy of radiotherapy by scheduling irradiations when the tumors are oxygenated. The repeated measurements of tumor pO2 may also identify responders, and thereby facilitate the design of better treatment plans for nonresponding tumors. We have investigated the temporal changes in the ectopic 9L and C6 glioma pO2 irradiated with single radiation doses less than 10 Gy by EPR oximetry. The 9L and C6 tumors were hypoxic with pO2 of approximately 5–9 mmHg. The pO2 of C6 tumors increased significantly with irradiation of 4.8–9.3 Gy. However, no change in the 9L tumor pO2 was observed. The irradiation of the oxygenated C6 tumors with a second dose of 4.8 Gy resulted in a significant delay in growth compared to hypoxic and 2 Gy × 5 treatment groups. The C6 tumors with an increase in pO2 of greater than 50% from the baseline of irradiation with 4.8 Gy (responders) had a significant tumor growth delay compared to nonresponders. These results indicate that the ectopic 9L and C6 tumors responded differently to radiotherapy. We propose that the repeated measurement of the oxygen levels in the tumors during radiotherapy can be used to identify responders and to design tumor oxygen guided treatment plans to improve the outcome.